BACKGROUND: Flavocoxid is a prescription medical food that is used to treat osteoarthritis. It is a proprietary blend of 2 flavonoids, baicalin and catechins, which are derived from the botanicals Scutellaria baicalensis and Acacia catechu, respectively. OBJECTIVE: To describe characteristics of patients with acute liver injury suspected of being caused by flavocoxid. DESIGN: Case series. SETTING: Drug-Induced Liver Injury Network Prospective Study ongoing at multiple academic medical centers since 2004. PATIENTS: Four adults with liver injury. MEASUREMENTS: Clinical characteristics, liver biochemistry values, and outcomes. RESULTS: Among 877 patients enrolled in the prospective study, 4 had liver injury suspected to have been caused by flavocoxid. All were women; ages ranged from 57 to 68 years. All developed symptoms and signs of liver injury within 1 to 3 months after initiating flavocoxid. Liver injury was characterized by marked elevations in levels of alanine aminotransferase (mean peak, 1268 U/L; range, 741 to 1540 U/L), alkaline phosphatase (mean peak, 510 U/L; range, 286 to 770 U/L), and serum bilirubin (mean peak, 160.7 µmol/L [9.4 mg/dL]; range, 34.2 to 356 µmol/L [2.0 to 20.8 mg/dL]). Liver biochemistry values decreased to the normal range within 3 to 12 weeks after flavocoxid was stopped, and all patients recovered without experiencing acute liver failure or chronic liver injury. Causality was adjudicated as highly likely in 3 patients and as possible in 1 patient. LIMITATION: The frequency and mechanism of liver injury could not be assessed. CONCLUSION: Flavocoxid can cause clinically significant liver injury, which seems to resolve within weeks after cessation.
BACKGROUND:Flavocoxid is a prescription medical food that is used to treat osteoarthritis. It is a proprietary blend of 2 flavonoids, baicalin and catechins, which are derived from the botanicals Scutellaria baicalensis and Acacia catechu, respectively. OBJECTIVE: To describe characteristics of patients with acute liver injury suspected of being caused by flavocoxid. DESIGN: Case series. SETTING:Drug-Induced Liver Injury Network Prospective Study ongoing at multiple academic medical centers since 2004. PATIENTS: Four adults with liver injury. MEASUREMENTS: Clinical characteristics, liver biochemistry values, and outcomes. RESULTS: Among 877 patients enrolled in the prospective study, 4 had liver injury suspected to have been caused by flavocoxid. All were women; ages ranged from 57 to 68 years. All developed symptoms and signs of liver injury within 1 to 3 months after initiating flavocoxid. Liver injury was characterized by marked elevations in levels of alanine aminotransferase (mean peak, 1268 U/L; range, 741 to 1540 U/L), alkaline phosphatase (mean peak, 510 U/L; range, 286 to 770 U/L), and serum bilirubin (mean peak, 160.7 µmol/L [9.4 mg/dL]; range, 34.2 to 356 µmol/L [2.0 to 20.8 mg/dL]). Liver biochemistry values decreased to the normal range within 3 to 12 weeks after flavocoxid was stopped, and all patients recovered without experiencing acute liver failure or chronic liver injury. Causality was adjudicated as highly likely in 3 patients and as possible in 1 patient. LIMITATION: The frequency and mechanism of liver injury could not be assessed. CONCLUSION:Flavocoxid can cause clinically significant liver injury, which seems to resolve within weeks after cessation.
Authors: M Schmidt; H-J Schmitz; A Baumgart; D Guédon; M I Netsch; M-H Kreuter; C B Schmidlin; D Schrenk Journal: Food Chem Toxicol Date: 2005-02 Impact factor: 6.023
Authors: Robert J Fontana; Paul B Watkins; Herbert L Bonkovsky; Naga Chalasani; Timothy Davern; Jose Serrano; James Rochon Journal: Drug Saf Date: 2009 Impact factor: 5.606
Authors: Sang-Won Park; Chan-Ho Lee; Yeong Shik Kim; Sam Sik Kang; Su Jin Jeon; Kun Ho Son; Sun-Mee Lee Journal: J Pharmacol Sci Date: 2008-01-11 Impact factor: 3.337
Authors: Allie Y Chen; Rebecca N Adamek; Benjamin L Dick; Cy V Credille; Christine N Morrison; Seth M Cohen Journal: Chem Rev Date: 2018-09-07 Impact factor: 60.622
Authors: William H Robinson; Christin M Lepus; Qian Wang; Harini Raghu; Rong Mao; Tamsin M Lindstrom; Jeremy Sokolove Journal: Nat Rev Rheumatol Date: 2016-08-19 Impact factor: 20.543
Authors: David S Goldberg; Kimberly A Forde; Dena M Carbonari; James D Lewis; Kimberly B F Leidl; K Rajender Reddy; Kevin Haynes; Jason Roy; Daohang Sha; Amy R Marks; Jennifer L Schneider; Brian L Strom; Douglas A Corley; Vincent Lo Re Journal: Gastroenterology Date: 2015-02-28 Impact factor: 22.682
Authors: Naga Chalasani; Herbert L Bonkovsky; Robert Fontana; William Lee; Andrew Stolz; Jayant Talwalkar; K Rajendar Reddy; Paul B Watkins; Victor Navarro; Huiman Barnhart; Jiezhun Gu; Jose Serrano Journal: Gastroenterology Date: 2015-03-06 Impact factor: 22.682
Authors: Naga Chalasani; K Rajender K Reddy; Robert J Fontana; Huiman Barnhart; Jiezhun Gu; Paul H Hayashi; Jawad Ahmad; Andrew Stolz; Victor Navarro; Jay H Hoofnagle Journal: Am J Gastroenterol Date: 2017-08-01 Impact factor: 10.864
Authors: Nury M Steuerwald; David M Foureau; H James Norton; Jie Zhou; Judith C Parsons; Naga Chalasani; Robert J Fontana; Paul B Watkins; William M Lee; K Rajender Reddy; Andrew Stolz; Jayant Talwalkar; Timothy Davern; Dhanonjoy Saha; Lauren N Bell; Huiman Barnhart; Jiezhun Gu; Jose Serrano; Herbert L Bonkovsky Journal: PLoS One Date: 2013-12-27 Impact factor: 3.240